Medikamentöse Therapien des Ulcus cruris

Zusammenfassung

Chronische Wunden belasten viele Patienten in Deutschland sowie weltweit. Medikamentöse Therapien spielen aktuell bei den häufigeren Ursachen wie dem Ulcus cruris venosum oder dem Ulcus cruris arteriosum noch eine untergeordnete Rolle, obwohl für einzelne Therapien gute Daten vorliegen. Für seltenere Krankheitsbilder wie Kalziphylaxie, Necrobiosis lipoidica und Pyoderma gangraenosum mangelt es oft an belastbaren Studien. Medikamentöse Behandlungen sind hier jedoch für die Abheilung essenziell. Insgesamt mangelt es bei allen genannten Erkrankungen an zugelassenen Therapien. In diesem Artikel werden mögliche medikamentöse Therapieoptionen bei allen genannten Erkrankungen diskutiert.

Abstract

Chronic wounds are a burden for many patients in Germany and around the world. Drug therapies still play a subordinate role for the more common causes such as venous leg ulcers or arterial leg ulcers, although good data is available for individual therapies. For rarer entities, such as calciphylaxis, necrobiosis lipoidica and pyoderma gangrenosum, there is often a lack of reliable studies. However, drug treatments are essential for healing in those cases. Overall, there is a lack of approved therapies for all the diseases mentioned. This article discusses possible drug therapy options for all the diseases mentioned.

Publication History

Article published online:
21 June 2024

• Literatur

• 1 Dissemond J, Bültemann A, Gerber V. et al. Standards für die Diagnostik und Therapie chronischer Wunden Stand 2020. Initiative Chronische Wunden. 2020 1–19
• 2 Dissemond J, Erfurt-Berge C, Goerge T. et al. Systemic therapies for leg ulcers. J Dtsch Dermatol Ges 2018; 16: 873-892 DOI: 10.1111/ddg.13586. (PMID: 29989361)
• 3 González-Consuegra RV, Verdú J. Quality of life in people with venous leg ulcers: An integrative review. J Adv Nurs 2011; 67: 926-944 DOI: 10.1111/j.1365-2648.2010.05568.x. (PMID: 21241355)
• 4 Margolis DJ, Bilker W, Santanna J. et al. Venous leg ulcer: Incidence and prevalence in the elderly. J Am Acad Dermatol 2002; 46: 381-386 DOI: 10.1067/mjd.2002.121739. (PMID: 11862173)
• 5 Fernandes Abbade LP, Lastória S. Venous ulcer: Epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol 2005; 44: 449-456
• 6 Jull A, Wadham A, Bullen C. et al. Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU). BMJ 2017; 359: j5157 DOI: 10.1136/bmj.j5157. (PMID: 29175902)
• 7 Helen T, Liz C, Laura C. et al. Aspirin versus placebo for the treatment of venous leg ulcers – A phase II, pilot, randomised trial (AVURT). Trials 2019; 20: 459 DOI: 10.1186/s13063-019-3480-7. (PMID: 31349862)
• 8 Weller CD, Martin C, Bouguettaya A. et al. Once daily 300 mg aspirin with compression versus compression alone in patients with chronic venous leg ulcers (ASPiVLU): A randomised, double-blinded, multicentre, placebo-controlled, clinical trial. J Tissue Viability 2021; 30: 509-516
• 9 Mulloy B, Hogwood J, Gray E. et al. Pharmacology of Heparin and Related Drugs. Pharmacol Rev 2015; 68: 76-141 DOI: 10.1124/pharmrev.122.000684. (PMID: 36792365)
• 10 Serra R, Buffone G, Molinari V. et al. Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. Int Wound J 2015; 12: 150-153
• 11 Jull AB, Arroll B, Parag V. et al. Pentoxifylline for treating venous leg ulcers. Cochrane Database of Systematic Reviews 2012; 12: CD001733 DOI: 10.1002/14651858.CD001733.pub3. (PMID: 23235582)
• 12 Shi C, Dumville JC, Cullum N. et al. Compression bandages or stockings versus no compression for treating venous leg ulcers. Cochrane Database Syst Rev 2021; 2021: CD013397 DOI: 10.1002/14651858.CD013397.pub2. (PMID: 34308565)
• 13 Evangelista MTP, Casintahan MFA, Villafuerte LL. Simvastatin as a novel therapeutic agent for venous ulcers: A randomized, double-blind, placebo-controlled trial. Brit J Dermatol 2014; 170: 1151-1157 DOI: 10.1111/bjd.12883. (PMID: 24506834)
• 14 Jull A, Lu H, Jiang Y. Statins and venous leg ulcer healing Secondary analysis of data from a cohort of three randomised controlled trials. Wound Repair and Regeneration 2021; 30: 186-189 DOI: 10.1111/wrr.12987. (PMID: 34894034)
• 15 Scallon C, Bell-Syer SEM, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev 2013; 2013: CD006477 DOI: 10.1002/14651858.CD006477.pub2. (PMID: 23728661)
• 16 O’Donnell TF, Passman MA, Marston WA. et al. Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum. J Vasc Surg 2014; 60: 3S-59S DOI: 10.1016/j.jvs.2014.04.049. (PMID: 24974070)
• 17 John J, Tate S, Price A. Non-surgical treatment for arterial leg ulcers: a narrative review. J Wound Care [Internet] 2022; 31: 969-978 DOI: 10.12968/jowc.2022.31.11.969. (PMID: 36367798)
• 18 Lawall H, Huppert P, Rümenapf G. et al. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. AWMF [Internet]. 2015
• 19 Norgren L, Hiatt WR, Dormandy JA. et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45: S5-S67 DOI: 10.1016/j.jvs.2006.12.037. (PMID: 17223489)
• 20 Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 2004; 33: 137-144 DOI: 10.1024/0301-1526.33.3.137. (PMID: 15461065)
• 21 Robertson I, Kessel DO, Berridge DC. Fibrinolytic agents for peripheral arterial occlusion. Vol. 2013, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2013
• 22 Schiffmann ML, Dissemond J, Erfurt-Berge C. et al. S1-Leitlinie Diagnostik und Therapie der Livedovaskulopathie. J Dtsch Dermatol Ges 2021; 19: 1667-1678 DOI: 10.1111/ddg.14520_g. (PMID: 34811901)
• 23 Weishaupt C, Strölin A, Kahle B. et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79
• 24 Nigwekar SU, Bloch DB, Nazarian RM. et al. Vitamin K-Dependent carboxylation of matrix gla protein influences the risk of calciphylaxis. Journal of the American Society of Nephrology 2017; 28: 1717-1722 DOI: 10.1681/ASN.2016060651. (PMID: 28049648)
• 25 Zitt E, König M, Vychytil A. et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrology Dialysis Transplantation 2013; 28: 1232-1240 DOI: 10.1093/ndt/gfs548. (PMID: 23291368)
• 26 Nigwekar SU, Brunelli SM, Meade D. et al. Sodium Thiosulfate therapy for Calcific Uremic Arteriolopathy. Clinical Journal of the American Society of Nephrology 2013; 8: 1162-1170 DOI: 10.2215/CJN.09880912. (PMID: 23520041)
• 27 Truong DH, Riedhammer MM, Zinszer K. Non-uraemic calciphylaxis successfully treated with pamidronate infusion. Int Wound J 2019; 16: 250-255 DOI: 10.1111/iwj.13019. (PMID: 30393969)
• 28 Fuchs F, Franke I, Tüting T. et al. Successful treatment of non-uremic calciphylaxis with bisphosphonate. J Dtsch Dermatol Ges 2020; 18: 1498-1500
• 29 Peng T, Zhuo L, Wang Y. et al. Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology 2018; 23: 669-675 DOI: 10.1111/nep.13081. (PMID: 28603903)
• 30 Ross EA. Evolution of treatment strategies for calciphylaxis. American Journal of Nephrology 2011; 34: 460-467 DOI: 10.1159/000332221. (PMID: 21986387)
• 31 Torregrosa JV, Sánchez-Escuredo A, Barros X. et al. Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates. Clin Nephrol 2015; 83: 231-234
• 32 Floege J, Kubo Y, Floege A. et al. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial. Clinical Journal of the American Society of Nephrology 2015; 10: 800-807 DOI: 10.2215/CJN.10221014. (PMID: 25887067)
• 33 Deen J, Schaider H. The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review. Australasian Journal of Dermatology 2019; 60: e186-e194 DOI: 10.1111/ajd.12992. (PMID: 30666627)
• 34 Russell R, Brookshire MA, Zekonis M. et al. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca P product and aggressive wound care. Clin Nephrol 2002; 58: 238-243 DOI: 10.5414/cnp58238. (PMID: 12356195)
• 35 El-Azhary RA, Arthur AK, Davis MDP. et al. Retrospective Analysis of Tissue Plasminogen Activator as an Adjuvant Treatment for Calciphylaxis. JAMA Dermatol [Internet] 2013; 149: 63-67 DOI: 10.1001/2013.jamadermatol.5. (PMID: 23324758)
• 36 Sewell LD, Weenig RH, Davis MDP. et al. Low-Dose Tissue Plasminogen Activator for Calciphylaxis. Arch Dermatol [Internet] 2004; 140: 1045-1048 DOI: 10.1001/archderm.140.9.1045. (PMID: 15381542)
• 37 Erfurt-Berge C, Dissemond J, Schwede K. et al. Updated results of 100 patients on clinical features and therapeutic options in necrobiosis lipoidica in a retrospective multicentre study. European Journal of Dermatology 2015; 25: 595-601 DOI: 10.1684/ejd.2015.2636. (PMID: 26575980)
• 38 Peckruhn M, Tittelbach J, Elsner P. Update: Therapie der Necrobiosis lipoidica. J Dtsch Dermatol Ges 2017; 15: 151-157 DOI: 10.1111/ddg.13186_g. (PMID: 28214306)
• 39 Erfurt-Berge C, Heusinger V, Reinboldt-Jockenhöfer F. et al. Comorbidity and Therapeutic Approaches in Patients with Necrobiosis Lipoidica. Dermatology 2022; 238: 148-155
• 40 Basoulis D, Fragiadaki K, Tentolouris N. et al. Anti-TNFα treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: A case report and review of the literature. Metabolism 2016; 65: 569-573 DOI: 10.1016/j.metabol.2015.12.014. (PMID: 26975548)
• 41 Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part II. A comprehensive review. Journal of the American Academy of Dermatology 2022; 86: 414-422 DOI: 10.1016/j.jaad.2021.06.873. (PMID: 34228996)
• 42 Erfurt-Berge C, Sticherling M. Successful treatment of ulcerative necrobiosis lipoidica with janus kinase inhibitor. Journal of the European Academy of Dermatology and Venereology 2020; 34: e329-e345 DOI: 10.1111/jdv.16297. (PMID: 32058637)
• 43 Arnet L, Erfurt-Berge C. Effect of abrocitinib in a patient with extensive necrobiosis lipoidica. Journal of the European Academy of Dermatology and Venereology 2023; 37: e1208-e1210
• 44 Jockenhöfer F, Wollina U, Salva KAA. et al. The PARACELSUS score: A novel diagnostic tool for pyoderma gangrenosum. Brit J Dermatol 2019; 180: 615-620 DOI: 10.1111/bjd.16401. (PMID: 29388188)
• 45 Maverakis E, Le ST, Callen J. et al. New validated diagnostic criteria for pyoderma gangrenosum. J Am Acad Dermatol 2019; 80: e87-e88 DOI: 10.1016/j.jaad.2018.08.068. (PMID: 30557582)
• 46 S1-Leitlinie Pyoderma gangraenosum. AWMF. 2020
• 47 Ormerod AD, Thomas KS, Craig FE. et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: Results of the STOP GAP randomised controlled trial. BMJ 2015; 350: h2958
• 48 Nazir A, Zafar A. Management of Idiopathic Pyoderma Gangrenosum With Azathioprine As the Primary Adjunct in an Asian Man: A Case Report. Cureus 2022; 14: e25177
• 49 Eaton PA, Callen JP. Mycophenolate Mofetil as Therapy for Pyoderma Gangrenosum. Arch Dermatol [Internet] 2009; 145: 781-785 DOI: 10.1001/archdermatol.2009.57. (PMID: 19620559)
• 50 Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis [Internet] 1996; 57: 326-328
• 51 Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: Systematic review of cases and case series. Brit J Dermatol 2018; 178: 363-368 DOI: 10.1111/bjd.15850. (PMID: 28742926)
• 52 Haag CK, Ortega-Loayza AG, Latour E. et al. Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. J Dermatolog Treat 2020; 31: 723-726 DOI: 10.1080/09546634.2019.1606888. (PMID: 30998080)
• 53 Brooklyn TN, Dunnill MGS, Shetty A. et al. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-509 DOI: 10.1136/gut.2005.074815. (PMID: 16188920)
• 54 Yamasaki K, Yamanaka K, Zhao Y. et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study. J Dermatol 2022; 49: 479-487
• 55 Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment. Am J Clin Dermatol 2017; 18: 555-562 DOI: 10.1007/s40257-017-0265-1. (PMID: 28236224)
• 56 Kolios AGA, Maul JT, Meier B. et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Brit J Dermatol 2015; 173: 1216-1223
• 57 Sun NZ, Ro T, Jolly P. et al. Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa. J Clin Aesthet Dermatol [Internet] 2017; 10: 36
• 58 Caproni M, Antiga E, Volpi W. et al. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Brit J Dermatol 2015; 173: 275-278
• 59 Burgdorf B, Schlott S, Ivanov IH. et al. Successful treatment of a refractory pyoderma gangrenosum with risankizumab. Int Wound J [Internet] 2020; 17: 1086-1088
• 60 Wollina U, Schönlebe J, Fürll C. Pyoderma gangrenosum induced by secukinumab – A late paradoxical drug reaction. Dermatol Ther [Internet] 2020; 33: e13161 DOI: 10.1111/dth.13161. (PMID: 31705566)
• 61 Guenova E, Teske A, Fehrenbacher B. et al. Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab. Arch Dermatol [Internet] 2011; 147: 1203-1205
• 62 Herberger K, Dissemond J, Brüggestrat S. et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum – analysis of 52 patients. J Dtsch Dermatol Ges 2019; 17: 32-41 DOI: 10.1111/ddg.13741. (PMID: 30592563)
• 63 Erfurt-Berge C, Renner R. Interdisziplinäres Vorgehen in Diagnostik und Therapie des Ulcus cruris. Aktuelle Derm [Internet] 2021; 47: 55-67